dm+d

388454007

Articles

Safety in Lactation: Insulins

23 September 2020Exogenous insulin is excreted into breast milk, including that from insulin analogues. Insulin in breast milk is thought to be necessary for intestinal maturation of…

Insulin preparations: RMOC recommendations of safety considerations for formulary decision making

22 June 2018At its meeting on 18th April 2018 the Regional Medicines Optimisation Committee (RMOC) (Midlands and East) reviewed issues pertaining to safety considerations when adopting any…
Search Articles

Refrigerated Storage

HumalogEli Lilly

Eli Lilly
Humalog
100 units/ml solution for injection (vial, cartridge and pre-filled pen) and 200 unit/ml pre-filled pen

In the event of an inadvertent temperature excursion the following data may be used:
The cartridge and pre-filled pens are stable when exposed to temperatures <30°C for 28 days. Do not return to the fridge.
The vials are stable when exposed to temperatures <30°C for 28 days. Following the excursion, the vials can be returned to the fridge or stored outside of the fridge (<30°C).
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Contact Eli Lilly in all other cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company details.

Reduce expiry to 28 days if exposed to the conditions above
29 September 2021
London MI Service

Lactation Safety Information

Yes
Likely to be degraded in infant's GI tract
Short-acting recombinant human insulin
11 September 2020

New Medicines

Lyumjev Type 1 and 2 diabetes mellitus in adolescents and children aged ≥1 year

Information

Lyumjev
Licence extension / variation
Eli Lilly
Eli Lilly

Development and Regulatory status

None
Recommended for approval (Positive opinion)
None
Oct 22CHMP recommends a change to the indications for Lyumjev to permit use in children from age 1 year (previously only licensed for use in adults). The proposed revised indication is for the treatment of “diabetes mellitus in adults, adolescents and children aged 1 year and above” [1].

Category

An ultra rapid formulation of insulin lispro, an analogue of human insulin
Currently more than 4.9 million people in the UK are diagnosed with diabetes (90% type 2), and it is estimated that a further 850,000 people with type 2 diabetes have not yet been diagnosed [2].
Type 1 and 2 diabetes mellitus in adolescents and children aged ≥1 year
Subcutaneous injection